Month: October 2021

Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors

- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts – - Monotherapy and pimivalimab combination dose escalation enrollment...

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence

- Dr. J. Chang, former Novartis Global Medical Affairs Head, Ophthalmology, to lead the advancement and expansion of Oculis’ pipeline...

error: Content is protected !!